Expert Opinion on Therapeutic Targets最新文献_第2页

The molecular role of RE1 silencing transcription factor in uterine diseases: is there potential for targeted therapeutic development? RE1沉默转录因子在子宫疾病中的分子作用：是否有靶向治疗发展的潜力？

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2025-09-01 Epub Date: 2025-09-10 DOI: 10.1080/14728222.2025.2557280

Warren B Nothnick, Vargheese Chennathukuzhi

引用次数: 0

Assessing the current molecular understanding of therapeutic targets in osteosarcoma. 评估目前对骨肉瘤治疗靶点的分子认识。

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2025-08-01 Epub Date: 2025-08-08 DOI: 10.1080/14728222.2025.2545836

Chao Zhang, Jilong Yang

{"title":"Assessing the current molecular understanding of therapeutic targets in osteosarcoma.","authors":"Chao Zhang, Jilong Yang","doi":"10.1080/14728222.2025.2545836","DOIUrl":"10.1080/14728222.2025.2545836","url":null,"abstract":"Introduction: Osteosarcoma, a highly aggressive bone tumor, continues to pose significant treatment challenges despite advances in molecular research. Traditional therapeutic strategies have largely relied on targeting genetic alterations of tumor genes or signaling pathways, but these approaches have been less effective in clinical settings due to the complex biology.Areas covered: Recent insights into the molecular landscape of osteosarcoma have revealed key mechanisms of therapeutic resistance, including tumor plasticity, immune evasion, and metabolic reprogramming. The interaction between the tumor and its microenvironment, such as mechanical stress, hypoxia, and extracellular matrix composition, leads to spatially distinct regions with varying drug sensitivities.Expert opinion: We highlight three key shifts in understanding osteosarcoma biology: 'target plasticity' driven by evolving tumor dynamics, the importance of mechanical signaling at the tumor-bone interface, and the potential of multi-omics platforms for real-time monitoring and personalized treatment. We propose a new therapeutic framework that integrates these advances to overcome resistance mechanisms. By focusing on epigenetic reprogramming, immune resetting, and mechanopharmacological approaches, we envision a more comprehensive strategy for osteosarcoma treatment that goes beyond traditional single-target therapies. The success of these strategies will depend on integrating spatially informed, time-resolved treatment regimens, guided by advanced molecular and computational technologies.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"527-536"},"PeriodicalIF":4.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144798602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular basis for targeting TBK1 in CAR-T cell therapies for cancer. 靶向TBK1的CAR-T细胞治疗癌症的分子基础。

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2025-08-01 Epub Date: 2025-08-19 DOI: 10.1080/14728222.2025.2545845

Giulia Cattaneo, Marco Ventin, Luke Maggs, Yi Sun, Cristina R Ferrone, Russell W Jenkins

引用次数: 0

Targeting transcription in neuroblastoma: focus on the core regulatory circuit. 神经母细胞瘤的靶向转录：关注核心调控回路。

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2025-08-01 Epub Date: 2025-08-25 DOI: 10.1080/14728222.2025.2545837

Oleg A Kuchur, Sofia S Pogodaeva, Victoria I Zhdankina, Anna V Scherbakova, Alexander A Shtil, Nadezhda V Antipova

{"title":"Targeting transcription in neuroblastoma: focus on the core regulatory circuit.","authors":"Oleg A Kuchur, Sofia S Pogodaeva, Victoria I Zhdankina, Anna V Scherbakova, Alexander A Shtil, Nadezhda V Antipova","doi":"10.1080/14728222.2025.2545837","DOIUrl":"10.1080/14728222.2025.2545837","url":null,"abstract":"Introduction: Neuroblastoma, a sympathetic nervous system tumor, is known for its remarkable biological heterogeneity. Unlike other neurogenic malignancies driven by mutations, neuroblastoma carries a significant 'transcriptional burden.' Deregulation of transcription unveils in the course of the tumor's natural history, making the advanced stages of the disease intractable.Areas covered: Recent research investigated the molecular profiles of key neuroblastoma states: adrenergic (ADRN) and mesenchymal (MES). These categories are defined by core regulatory circuit (CRC) genes whose products (transcription factors) modulate a variety of malignant properties. This review analyzes fundamental mechanisms of regulation of CRC in neuroblastoma, focusing on transcriptional alterations as tentative therapeutic targets. We dissect differential CRC patterns in ADRN and MES states and discuss opportunities for therapeutic combinations targeting CRC along with other survival mechanisms.Expert opinion: We emphasize the critical importance of combined CRC inactivation as a promising therapeutic avenue. This approach is substantiated by basic biological mechanisms largely demonstrated in experimental models. Although the detailed roles of CRC in individual clinical situations remain to be elucidated, interference with the subtype-specific patterns of CRC-dependent gene expression, together with inactivation of an additional survival factor(s), offers new opportunities for mechanism-based, personalized treatment.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"579-595"},"PeriodicalIF":4.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rhabdomyosarcoma: development of molecular therapeutics under the microscope. 横纹肌肉瘤：显微镜下分子疗法的发展。

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2025-08-01 Epub Date: 2025-08-27 DOI: 10.1080/14728222.2025.2551106

Peter J Houghton, Mary-Ann Bjornsti

{"title":"Rhabdomyosarcoma: development of molecular therapeutics under the microscope.","authors":"Peter J Houghton, Mary-Ann Bjornsti","doi":"10.1080/14728222.2025.2551106","DOIUrl":"10.1080/14728222.2025.2551106","url":null,"abstract":"Introduction: Rhabdomyosarcoma (RMS), predominantly diagnosed in children, represents 3% of the pediatric solid tumors. RMS has characteristics of skeletal muscle, although the cell of origin remains controversial. Cytotoxic therapeutics, radiation treatment and surgery remain the standard of care; however, outcomes for advanced disease have not changed for several decades. Major research advances over the past two decades have defined molecular subtypes and driver mutations that could provide new therapeutic targets.Areas covered: Due to the small number of patients diagnosed with RMS, progress in testing novel agents has been slow and, although many drugs with 'molecular targets' have been identified as 'active' in preclinical models, there remains a lack of standardization for evaluating efficacy. Molecular therapeutics identified in model systems include kinase inhibitors, antibody-drug conjugates (ADCs), chimeric antigen receptor T-cells (CAR T-cells), and drugs that target the genetic/epigenetic drivers of RMS. More recently, immune checkpoint inhibitors have entered clinical trials.Expert opinion: RMS represents a set of diseases with unique molecular drivers that will each necessitate the development of targeted therapeutics. For efficient development of effective treatments, novel approaches to preclinical testing and standardization of efficacy assessments need to be developed in conjunction with molecularly guided clinical trials in patients earlier in their disease before drug resistance develops.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"537-555"},"PeriodicalIF":4.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144948097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Serum sodium and cancer: an underrated prognostic and predictive biomarker? 血清钠与癌症：一个被低估的预后和预测性生物标志物？

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2025-08-01 Epub Date: 2025-08-07 DOI: 10.1080/14728222.2025.2545841

Giandomenico Roviello, Martina Catalano

引用次数: 0

RBM47 as a therapeutic target in selected human diseases. RBM47作为特定人类疾病的治疗靶点。

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2025-08-01 Epub Date: 2025-08-09 DOI: 10.1080/14728222.2025.2545843

Valerie Blanc, Nicholas O Davidson

引用次数: 0

Potential therapeutic targets and biomarkers in testicular germ cell tumor oncogenesis. 睾丸生殖细胞肿瘤肿瘤发生的潜在治疗靶点和生物标志物。

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2025-08-01 Epub Date: 2025-09-02 DOI: 10.1080/14728222.2025.2551105

Francesco Esposito, Marco De Martino, Viviana Franco, Alfredo Fusco, Paolo Chieffi

{"title":"Potential therapeutic targets and biomarkers in testicular germ cell tumor oncogenesis.","authors":"Francesco Esposito, Marco De Martino, Viviana Franco, Alfredo Fusco, Paolo Chieffi","doi":"10.1080/14728222.2025.2551105","DOIUrl":"10.1080/14728222.2025.2551105","url":null,"abstract":"Introduction: The most prevalent solid cancer in young adult males is testicular germ cell tumors (TGCTs), which are becoming more and more common globally. Approximately 20% of patients with metastatic disease relapse or develop resistance to cisplatin-based chemotherapy, despite its high effectiveness, underscoring the need for alternative therapies.Areas covered: With an emphasis on new molecular targets and biomarkers, this review describes developments in TGCT pathophysiology and treatment. Tyrosine kinase receptors, transcription factors, elements of the DNA damage response, and cell cycle regulators are important oncogenic drivers. CDK inhibitors, PARP inhibitors, and Aurora kinase antagonists are promising early-stage agents. Meanwhile, noninvasive liquid biopsy techniques are being made possible by biomarkers like CLDN6, cfDNA/ctDNA, and the miR-371 ~ 373 cluster, which may enhance disease monitoring, risk assessment, and diagnosis.Expert opinion: Although the majority of TGCT cases have positive results, cisplatin-refractory disease continues to be a significant therapeutic challenge. A route to precision medicine is provided by molecular profiling and biomarker-driven approaches. However, implementation requires clinical validation, patient selection, and standardization. The landscape of TGCT treatment may change over the next 10 years as a result of the integration of targeted therapies and molecular diagnostics, which may greatly increase survival rates while lowering long-term toxicity.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"567-578"},"PeriodicalIF":4.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Uncovering immune pathways for therapeutic targeting of hypertension. 揭示高血压靶向治疗的免疫途径。

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2025-08-01 Epub Date: 2025-08-21 DOI: 10.1080/14728222.2025.2549564

Katherine S Deck, Christoph J Mora, Shuoqiu Deng, Pamela Rogers, Tonya M Rafferty, Philip Palade, Yunmeng Liu, Shengyu Mu

{"title":"Uncovering immune pathways for therapeutic targeting of hypertension.","authors":"Katherine S Deck, Christoph J Mora, Shuoqiu Deng, Pamela Rogers, Tonya M Rafferty, Philip Palade, Yunmeng Liu, Shengyu Mu","doi":"10.1080/14728222.2025.2549564","DOIUrl":"10.1080/14728222.2025.2549564","url":null,"abstract":"Introduction: Hypertension is a major health problem worldwide, yet fewer than half of patients maintain adequate blood-pressure control, pointing to hidden pathogenic drivers and therapeutic gaps. Normal pressure regulation depends on seamless cross-talk among the kidney, vasculature, brain, and gut; once this dialogue falters, low-grade, T cell-centered inflammation sustains disease.Areas covered: In the kidney, CD8 + T cells bearing the purinergic receptor P2X7sense extracellular ATP and hypertonicity, upregulate renal sodium transporters, and lock in salt. Perivascular adipose tissue mobilizes monocytes, γδ T cells, and B cells that, through CCL5-guided trafficking and IFN-γ/IL-17A release, heighten oxidative stress and endothelial dysfunction - defects reversible by regulatory T-cell transfer. In the central nervous system, angiotensin II and dietary salt skew microglia toward a pro-inflammatory state, breach the blood-brain barrier and attract Th17 and γδ T cells, establishing a sympathetic feed-forward loop. Concurrent gut dysbiosis - marked by excess short-chain fatty acids and dwindling aryl-hydrocarbon metabolites - reprograms macrophage and T-cell phenotypes, reinforcing systemic inflammation.Expert opinion: Targeting these inter-organ immune circuits, especially activation and infiltration of T cells and inflammasome, will provide precise immunomodulatory strategies poised to deliver enduring blood-pressure control and cardiovascular protection.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"557-566"},"PeriodicalIF":4.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144882425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rare tumors, real targets: patient-derived models for the discovery and validation of precision therapies. 罕见肿瘤，真正的目标：发现和验证精确治疗的患者衍生模型。

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2025-08-01 Epub Date: 2025-08-28 DOI: 10.1080/14728222.2025.2551116

Nathan P Coussens, Beverly A Teicher

引用次数: 0